[Radiation-induced and therapy-related AML/MDS].
Radiation induced acute myeloid leukemia (AML) was recognized a century ago, soon after mankind found radiation. Atomic bomb survivors developed de novo AML with relatively short latency with very high frequency. By contrast, excess occurrence of myelodysplastic syndrome (MDS) as well as solid tumors was found decades late. This difference may be due to etiology that many de novo AML patients harbor chimeric leukemogenic genes caused by chromosomal translocations, while MDS patients rarely carry chimeras. In addition, epigenetic change would play important roles. Therapy related leukemia is mainly caused by topoisomerase II inhibitors that cause de novo AML with an 11q23 translocation or by alkyrating agents that induce MDS/AML with an AML1 point mutation and monosomy 7.
Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University.
Toshiya
T
Inaba
D000477:Alkylating Agents / Q000009:adverse effects; D002678:Chimera / Q000235:genetics; D004791:Enzyme Inhibitors / Q000009:adverse effects; D044127:Epigenesis, Genetic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000209:etiology*; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology / Q000209:etiology*; D009190:Myelodysplastic Syndromes / Q000453:epidemiology / Q000209:etiology*; D054043:Nuclear Weapons; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic
D000477:Alkylating Agents; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors